DLBS 1449

Drug Profile

DLBS 1449

Alternative Names: DLBS1449; Forhidrol

Latest Information Update: 17 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dexa Medica
  • Class Antihyperlipidaemics; Phytotherapies
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Dyslipidaemias

Most Recent Events

  • 03 Aug 2016 Dexa Medica withdraws a phase II/III trial for Dyslipidaemias in Indonesia prior to enrolment (NCT01972477)
  • 16 Dec 2013 Dexa Medica plans a phase II/III trial for Dyslipidaemias in Indonesia (NCT01972477)
  • 01 Oct 2013 Clinical trials in Dyslipidaemias in Indonesia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top